Abstract: A demagnetization method, device, and magnet. The demagnetization method includes applying a decaying alternating magnetic field to a permanent magnet, where a direction of the decaying alternating magnetic field forms a predetermined angle with a magnetization direction of the permanent magnet, and the predetermined angle ranges from 45° to 135°.

Abstract: A high-coercivity and high-remanence NdFeB magnet includes R, M, B, and Fe, R includes RL and RH, RL includes at least one of Pr, Nd, La, Ce, or Y, RH includes at least one of Dy, Tb, Gd, or Ho, M includes Co, Cu, and M?, and M? includes at least one of Cr, Ni, Ga, Al, Zr, Nb, or Ti. The NdFeB magnet includes R2 T14B main phase grains and grain boundary phase A, R content in the grain boundary phase A is in a range of 29 at % to 55 at %, Co content in the grain boundary phase A is in a range of 3 at % to 7 at %, Cu content in the grain boundary phase A is in a range of 7 at % to 20 at %.

Abstract: An NdFeB magnet includes R, M, and T. T includes Fe. R includes at least one of Nd, Pr, La, Ce, or Y. M includes at least one of Cr, Co, Ni, Ga, Cu, Ti, Al, Zr, or Nb. The NdFeB magnet includes R2T14B main phase grains, thin-layer grain boundary phases, and triangular region grain boundary phases. The triangular region grain boundary phases include first intergranular boundary phases and second intergranular boundary phases. R content in the first intergranular boundary phases is less than 30 at %, and R content in the second intergranular boundary phases is greater than 30 at %. On any cross-section of the magnet, a area of the first intergranular boundary phases is in a range of 65% to 86% of a total area of the triangular region grain boundary phases.

Abstract: The disclosure provides, e.g., compositions, systems, and methods for targeting, editing, modifying, or manipulating a host cell's genome at one or more locations in a DNA sequence in a cell, tissue, or subject. Gene modifying systems for treating phenylketonuria (PKU) are described.

Abstract: A bonded magnet, a composition for preparing bonded magnets, and a method for preparing adhesive magnets using the composition. The bonded magnet includes magnetic powder and a binder. The binder includes a vitrimer. A content of the magnetic powder ranges from 96 wt % to 98 wt % and a content of the binder ranges from 0.89 wt % to 2.17 wt %. The composition includes magnetic powder, a polymer precursor, a crosslinking agent, and a catalyst capable of catalyzing a crosslinking reaction between the crosslinking agent and the polymer precursor to form a dynamically crosslinked network structure.

Abstract: Provided in the present application are a C-arm imaging system and a tube assembly mounting method. The C-arm imaging system includes a C-arm, a tube assembly, a detector assembly, and a rotation assembly. The C-arm includes an inner surface and an outer surface disposed opposite to each other. The tube assembly is located at a first end of the C-arm, and is mounted on the inner surface of the C-arm. The detector assembly is located at a second end of the C-arm opposite to the first end. The rotation assembly is mounted on the outer surface of the C-arm. The C-arm is movable relative to the rotation assembly, and an outer surface opposite to an inner surface on which the tube assembly is located is slidable relative to the rotation assembly.

Abstract: The present application provides a total knee arthroplasty robot auxiliary system, a control method, electronic device and a computer readable medium.

Abstract: Various aspects of methods, systems, and use cases may be used to generate an ear disease state prediction to assist diagnosis of an ear disease. A method may include receiving an image an ear, predicting an image-based confidence level of a disease state in the ear by using the image as in input to a machine learning trained model. The method may include receiving text, for example corresponding to a symptom of the patient. The method may include predicting a symptom-based confidence level of the disease state in the ear by using the text as in input to a trained classifier. The method may include using the results of the image-based confidence level and the symptom-based confidence level to determine an overall confidence level of presence of an ear infection in the ear of the patient.

Abstract: The disclosure provides, e.g., compositions, systems, and methods for targeting, editing, modifying, or manipulating a host cell's genome at one or more locations in a DNA sequence in a cell, tissue, or subject. Gene modifying systems for treating cystic fibrosis, e.g., in subjects having a mutation resulting in F508del, are described.

Abstract: A neodymium-iron-boron flexible magnet includes 93.5 wt % to 94.6 wt % of neodymium-iron-boron magnetic powder, 0.3 wt % to 0.5 wt % of surface treatment agent for magnetic powder, 2.7 wt % to 3.7 wt % of binder, 0.3 wt % to 1.0 wt % of antioxidant, and 0.5 wt % to 1.8 wt % of plasticizer. The binder includes type I thermoplastic elastomer and type II thermoplastic elastomer, with a mass ratio of the type I thermoplastic elastomer to the type II thermoplastic elastomer being 1:9 to 4:6. The type I thermoplastic elastomer is selected from one or more of thermoplastic polyamide elastomer and thermoplastic polyurethane elastomer; and the type II thermoplastic elastomer is selected from one or more of styrenic block copolymers, dynamically vulcanized thermoplastic elastomers, thermoplastic polyolefin elastomers, and thermoplastic polyester elastomers.

Abstract: The disclosure provides, e.g., compositions, systems, and methods for targeting, editing, modifying, or manipulating a host cell's genome at one or more locations in a DNA sequence in a cell, tissue, or subject. Gene modifying systems for treating cystic fibrosis, e.g., in subjects having a mutation resulting in F508del, are described.

Abstract: Ionizable lipids and lipid nanoparticles comprising ionizable lipids are provided herein. Also provided are methods for making and using the lipid nanoparticles for delivery to a cell one or more payload agents, including polypeptides, mRNAs such as mRNA encoding Cas9 nuclease, and guide RNAs comprising backbone, sugar or base modifications.

Abstract: This invention relates to a method for entire removal of a space truss, and an assistive support mechanism therefor. The assistive support mechanism is arranged on a vertical support rod of a truss structure, the assistive support mechanism comprises an assistive support assembly, a lattice support member, and a conversion platform. The lifting assembly is arranged at a top of the conversion platform and comprises a stranded wire, a lifting member, and a control member. The method for entire removal of a space truss comprises mounting the assistive support mechanism, and performing initial removal of the truss structure; lowering the truss structure; and then performing secondary removal of the entire space truss. The major removal work is done on the ground, thereby reducing the requirement for removal-assisting measures and the operational risks, and improving the working efficiency.

Abstract: An improvement in the telemedicine-based diagnosis of acute otitis media is discussed. The improvement including a system and method for merging an otoscope video stream into a telemedicine session. Operations for merging the otoscope video stream can being with initiating a telemedicine session. Subsequently, the system can determine, from within the telemedicine session, whether a connection to an otoscope providing the otoscope video stream is available. If the video stream is available, the system can access the otoscope video stream within the telemedicine session.

Abstract: A NdFeB rare earth magnet includes a main phase and a grain boundary phase including a white grain boundary phase and a gray grain boundary phase. In a microstructure observation area of the rare earth magnet, an area of the white grain accounts for 1˜3% of a total area of the microstructure observation area, and an area of the gray grain boundary phase accounts for 2˜10% of the total area of the microstructure observation area.

Abstract: Provided herein are encapsulated liposomes comprising a lipid bilayer, a first polyethylene glycol (PEG) corona, a targeting molecule and a second PEG corona. The second, encapsulating PEG corona can be reversibly linked to the first PEG corona. Also provided are pharmaceutical compositions comprising the encapsulated liposomes and methods of treating a subject with a disease characterized by production of reactive oxygen species (ROS) with the compositions. Also provided are methods of making the encapsulated liposomes disclosed herein.

Abstract: The disclosure provides, e.g., compositions, systems, and methods for targeting, editing, modifying, or manipulating a host cell's genome at one or more locations in a DNA sequence in a cell, tissue, or subject. Gene modifying systems for treating sickle cell disease (SCD) are described.

Abstract: The disclosure provides, e.g., compositions, systems, and methods for targeting, editing, modifying, or manipulating a host cell's genome at one or more locations in a DNA sequence in a cell, tissue, or subject. Gene modifying systems for treating cystic fibrosis, e.g., in subjects having a mutation resulting in F508del, are described.

Abstract: The disclosure provides, e.g., compositions, systems, and methods for targeting, editing, modifying, or manipulating a host cell's genome at one or more locations in a DNA sequence in a cell, tissue, or subject. Gene modifying systems for treating phenylketonuria (PKU) are described.

Abstract: The disclosure provides, e.g., compositions, systems, and methods for targeting, editing, modifying, or manipulating a host cell's genome at one or more locations in a DNA sequence in a cell, tissue, or subject. Gene modifying systems for treating alpha-1 antitrypsin deficiency (AATD) are described.